BR112013003875B1 - Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos - Google Patents

Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos Download PDF

Info

Publication number
BR112013003875B1
BR112013003875B1 BR112013003875-6A BR112013003875A BR112013003875B1 BR 112013003875 B1 BR112013003875 B1 BR 112013003875B1 BR 112013003875 A BR112013003875 A BR 112013003875A BR 112013003875 B1 BR112013003875 B1 BR 112013003875B1
Authority
BR
Brazil
Prior art keywords
oligonucleotides
oligonucleotide
chelate complex
rep
calcium
Prior art date
Application number
BR112013003875-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013003875A2 (en
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013003875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of BR112013003875A2 publication Critical patent/BR112013003875A2/en
Publication of BR112013003875B1 publication Critical patent/BR112013003875B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
BR112013003875-6A 2010-08-20 2011-08-18 Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos BR112013003875B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
US61375257 2010-08-20
US61/375,257 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Publications (2)

Publication Number Publication Date
BR112013003875A2 BR112013003875A2 (en) 2018-03-13
BR112013003875B1 true BR112013003875B1 (pt) 2021-10-05

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003875-6A BR112013003875B1 (pt) 2010-08-20 2011-08-18 Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos

Country Status (35)

Country Link
US (2) US8513211B2 (https=)
EP (1) EP2605794B1 (https=)
JP (1) JP5775581B2 (https=)
KR (3) KR101606495B1 (https=)
CN (2) CN103768086B (https=)
AU (1) AU2011291401B2 (https=)
BR (1) BR112013003875B1 (https=)
CA (2) CA2806616C (https=)
CL (1) CL2013000445A1 (https=)
CO (1) CO6670525A2 (https=)
CR (1) CR20130069A (https=)
CU (1) CU20130022A7 (https=)
CY (1) CY1118207T1 (https=)
DK (1) DK2605794T3 (https=)
DO (1) DOP2013000041A (https=)
EA (1) EA026660B1 (https=)
EC (1) ECSP13012449A (https=)
ES (1) ES2598556T3 (https=)
GT (1) GT201300040A (https=)
HR (1) HRP20161333T1 (https=)
HU (1) HUE029521T2 (https=)
IL (1) IL224237A (https=)
LT (1) LT2605794T (https=)
MX (1) MX340294B (https=)
MY (1) MY160961A (https=)
NZ (1) NZ606364A (https=)
PH (1) PH12013500192B1 (https=)
PL (1) PL2605794T3 (https=)
PT (1) PT2605794T (https=)
RS (1) RS55245B1 (https=)
SG (1) SG187165A1 (https=)
SI (1) SI2605794T1 (https=)
SM (1) SMT201600370B (https=)
WO (1) WO2012021985A1 (https=)
ZA (1) ZA201300497B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007282224B2 (en) 2006-08-11 2013-08-29 Vico Therapeutics B.V. Methods and means for treating DNA repeat instability associated genetic disorders
CA2723672C (en) 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
SMT201700339T1 (it) 2012-04-23 2017-09-07 Biomarin Tech Bv Oligonucleotidi di modulazione dell'rna con caratteristiche migliorate per il trattamento dei disturbi neuromuscolari
EP3511022A1 (en) * 2012-05-10 2019-07-17 Adynxx, Inc. Formulations for the delivery of active ingredients
MY168778A (en) * 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
EP2870246B1 (en) 2012-07-03 2019-09-11 BioMarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
AU2013308045B2 (en) * 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
HRP20231400T1 (hr) 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
AU2016250576C1 (en) * 2015-04-23 2021-05-06 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
PE20211783A1 (es) * 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
WO2021198958A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Nucleic acid polymers
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
EP4367241A1 (en) 2021-07-09 2024-05-15 GlaxoSmithKline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514873A (ja) * 1997-08-20 2001-09-18 ソーマジェニックス インコーポレイテッド 結合特性が改善されたアンチセンスおよびアンチジーン治療薬並びにそれらの使用方法
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US20070105116A1 (en) 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid
WO2005026188A1 (ja) 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
JP2009500020A (ja) * 2005-07-01 2009-01-08 バイオヴェリス コーポレイション 核酸を検出、増幅および／また単離するための組成物および方法
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Also Published As

Publication number Publication date
NZ606364A (en) 2014-12-24
DOP2013000041A (es) 2017-12-15
WO2012021985A1 (en) 2012-02-23
EP2605794A1 (en) 2013-06-26
PL2605794T3 (pl) 2017-01-31
SG187165A1 (en) 2013-02-28
HK1198123A1 (en) 2015-03-13
HUE029521T2 (en) 2017-03-28
CN103768086A (zh) 2014-05-07
CN103768086B (zh) 2015-10-14
AU2011291401A1 (en) 2013-01-10
JP2013536195A (ja) 2013-09-19
CA2806616C (en) 2015-08-11
PH12013500192B1 (en) 2018-11-23
CA2855690C (en) 2015-08-25
US8513211B2 (en) 2013-08-20
IL224237A (en) 2015-09-24
BR112013003875A2 (en) 2018-03-13
MY160961A (en) 2017-03-31
HRP20161333T1 (hr) 2016-12-02
AU2011291401B2 (en) 2014-11-27
US8716259B2 (en) 2014-05-06
CR20130069A (es) 2013-09-20
MX2013001668A (es) 2013-07-22
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
ECSP13012449A (es) 2013-04-30
KR20150039873A (ko) 2015-04-13
PT2605794T (pt) 2016-10-25
RS55245B1 (sr) 2017-02-28
MX340294B (es) 2016-07-04
US20130296410A1 (en) 2013-11-07
US20120046348A1 (en) 2012-02-23
KR101606495B1 (ko) 2016-03-28
EA201300259A1 (ru) 2013-12-30
CN103052405A (zh) 2013-04-17
HK1184058A1 (zh) 2014-01-17
CO6670525A2 (es) 2013-05-15
KR20150082685A (ko) 2015-07-15
SMT201600370B (it) 2016-11-10
EP2605794B1 (en) 2016-07-20
CA2855690A1 (en) 2012-02-23
EP2605794A4 (en) 2014-07-02
EA026660B1 (ru) 2017-05-31
ZA201300497B (en) 2013-09-25
CU20130022A7 (es) 2013-04-19
DK2605794T3 (en) 2016-10-24
GT201300040A (es) 2014-09-02
CA2806616A1 (en) 2012-02-23
JP5775581B2 (ja) 2015-09-09
PH12013500192A1 (https=) 2013-03-11
CN103052405B (zh) 2015-11-25
LT2605794T (lt) 2016-10-25
KR20130099067A (ko) 2013-09-05
SI2605794T1 (sl) 2017-01-31
CL2013000445A1 (es) 2013-11-22

Similar Documents

Publication Publication Date Title
BR112013003875B1 (pt) Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
ES2767333T3 (es) Métodos de complejos de quelatos de oligonucleótidos
HK1184058B (en) Oligonucleotide chelate complexes
HK1198123B (en) The use of oligonucleotide chelate complexes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.